Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September 10, 2018-Temple, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations. Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until now.

/ckfinder/userfiles/files/Press%20Release_Sept13_2018.pdf